 Your new post is loading...
 Your new post is loading...
|
Scooped by
Ed Rybicki
February 22, 2019 2:29 AM
|
An analysis of cervical precancers over a period of seven years showed that two strains of human papillomavirus (HPV) that have been targeted by vaccination since 2006 have declined, accounting for a smaller proportion of ...
|
Scooped by
Ed Rybicki
February 22, 2019 2:28 AM
|
Reversing an earlier decision, the World Health Organization (WHO) now recommends vaccinating pregnant and breastfeeding women against the Ebola virus.
|
Scooped by
Ed Rybicki
February 22, 2019 2:27 AM
|
“(. . .) A subset of white blood cells called ‘killer’ T cells can provide immunity across all the different types of influenza viruses that can...
|
Scooped by
Ed Rybicki
February 22, 2019 2:26 AM
|
Nigeria's health systems are overwhelmed and incapable of sustaining high quality disease surveillance, prevention, control and response.
|
Scooped by
Ed Rybicki
February 19, 2019 6:06 AM
|
To complicate matters, people are able to create virtual communities of like-minded individuals who seek out information sources that they feel comfortable with.
|
Scooped by
Ed Rybicki
February 19, 2019 6:05 AM
|
Sure, it came on the heels of World War I, but it was way more deadly.
|
Scooped by
Ed Rybicki
February 19, 2019 6:04 AM
|
DOH says the number of deaths has climbed to 136, nearly double the number in just 7 days...
|
Scooped by
Ed Rybicki
February 7, 2019 10:12 AM
|
All trainers should put in place strict biosecurity measures as advised in the NTF Biosecurity Guidelines. CLICK ON THE LOGO TO READ This is also contained in the Code of Practice for Infectious Disease on the EquiBioSafe app
|
Scooped by
Ed Rybicki
February 7, 2019 10:08 AM
|
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed...
|
Scooped by
Ed Rybicki
February 6, 2019 10:57 AM
|
With a growing world population, increasingly demanding consumers, and a limited amount of agricultural land, there is an urgent need to find alternatives to conventional meat products
|
Scooped by
Ed Rybicki
February 6, 2019 2:06 AM
|
During a measles virus (MeV) epidemic in 2009 in South Africa, measles inclusion body encephalitis (MIBE) was identified in several HIV-infected patients. Years later, children are presenting with subacute sclerosing panencephalitis (SSPE). To investigate the features of established MeV neuronal infections, viral sequences were analyzed from brain tissue samples of a single SSPE case and compared with MIBE sequences previously obtained from patients infected during the same epidemic. Both the SSPE and the MIBE viruses had amino acid substitutions in the ectodomain of the F protein that confer enhanced fusion properties. Functional analysis of the fusion complexes confirmed that both MIBE and SSPE F protein mutations promoted fusion with less dependence on interaction by the viral receptor-binding protein with known MeV receptors. While the SSPE F required the presence of a homotypic attachment protein, MeV H, in order to fuse, MIBE F did not. Both F proteins had decreased thermal stability compared to that of the corresponding wild-type F protein. Finally, recombinant viruses expressing MIBE or SSPE fusion complexes spread in the absence of known MeV receptors, with MIBE F-bearing viruses causing large syncytia in these cells. Our results suggest that alterations to the MeV fusion complex that promote fusion and cell-to-cell spread in the absence of known MeV receptors is a key property for infection of the brain. IMPORTANCE Measles virus can invade the central nervous system (CNS) and cause severe neurological complications, such as MIBE and SSPE. However, mechanisms by which MeV enters the CNS and triggers the disease remain unclear. We analyzed viruses from brain tissue of individuals with MIBE or SSPE, infected during the same epidemic, after the onset of neurological disease. Our findings indicate that the emergence of hyperfusogenic MeV F proteins is associated with infection of the brain. We also demonstrate that hyperfusogenic F proteins permit MeV to enter cells and spread without the need to engage nectin-4 or CD150, known receptors for MeV that are not present on neural cells.
|
Scooped by
Ed Rybicki
February 2, 2019 6:00 AM
|
Efforts to prevent children with chronic lung disease being hospitalised with influenza need to be stepped up following high rates of flu hospitalisation in these children. This is one of the recommendations of a UNSW study that found children with underlying lung conditions such as asthma, cystic fibrosis, bronchopulmonary dysplasia and other congenital chronic conditions are at least five times more at risk of being hospitalised with influenza than other children. The study, which looked at a cohort of 11,058 children with chronic lung diseases residing in NSW, found that not only are children with chronic lung disease substantially more at risk of hospitalisation from flu, but the average cost of these hospitalisations is almost four times more expensive. The cost per episode of influenza-associated hospitalisation was $19,704 for children with chronic lung diseases compared to $4557 for children without. In addition, 13% of children with chronic lung condition hospitalised with influenza required referral to another hospital for ongoing care compared to 7% without. Study lead author Dr Nusrat Homaira from UNSW’s School of Women’s and Children’s Health says despite the fact that vaccination against influenza is free for children with chronic lung conditions, unpublished data suggests uptake is low and more needs to be done to encourage parents of children with the condition to take advantage of the service. “Influenza is a vaccine preventable disease and Australian children with chronic lung disease are entitled to free flu vaccination,” Dr Homaira says. “However the uptake – particularly in children with asthma – is reported to be very low. Our research suggests that current efforts to prevent flu in children with chronic lung conditions are either suboptimal or ineffective.” Dr Homaira and her co-authors say an immediate first step is to conduct further research into the effectiveness of vaccine in these children and to look for ways to improve vaccine uptake. “Vaccination against influenza is highly recommended for children with chronic lung conditions and the vaccine should be repeated every year for these children”,” Dr Homaira says. The research paper was published in the Influenza and Other Respiratory Viruses journal.
|
Scooped by
Ed Rybicki
February 2, 2019 5:59 AM
|
Japan’s Ministry of Health, Labour and Welfare said on Friday that the nation is contending with a flu epidemic with a record-high number of patients being...
|
|
Scooped by
Ed Rybicki
February 22, 2019 2:29 AM
|
Widespread misunderstanding of the nature of science and the confirmation bias spawned by social media and the internet can have dire consequences to public health.
|
Scooped by
Ed Rybicki
February 22, 2019 2:27 AM
|
North Dakota Senator Kevin Cramer (R-ND) falsely claimed Barack Obama invoked a national emergency for “no reason” Feb 19, only to get brutally fact-checked by the Associated Press Thursday. “Barack Obama declared a national emergency to fight swine flu and we didn’t have a single case of it in...
|
Scooped by
Ed Rybicki
February 22, 2019 2:27 AM
|
The World Health Organization (WHO) issued its recommendations on the composition of the influenza vaccines for deployment during the 2019-2020 flu season in the Northern Hemisphere. This is important news since approximately 90 percent of the world’s population live in the Northern Hemisphere.
|
Scooped by
Ed Rybicki
February 19, 2019 6:06 AM
|
The U.S. Food and Drug Administration (FDA) approved baloxavir marboxil, an oral tablet to be marketed as Xofluza, for treatment of early acute uncomplicated influenza in adolescents and adults.FD…...
|
Scooped by
Ed Rybicki
February 19, 2019 6:05 AM
|
Pneumonia is one of the leading causes of death in children under five, killing more children annually than HIV, TB and malaria combined. The KEMRI-Wellcome Trust Research Programme and partners, including the London School of Hygiene & Tropical Medicine, collaborated on the Pneumococcal...
|
Scooped by
Ed Rybicki
February 19, 2019 6:04 AM
|
Scientists said Monday they had discovered immune cells that can fight all known flu viruses in what was hailed as an “extraordinary breakthrough” that could lead to a universal, one-shot vaccine against the killer disease.
|
Scooped by
Ed Rybicki
February 7, 2019 10:13 AM
|
The Center for Disease Control and Prevention, the main national public health institute in the United States, has a zombie preparedness guide. When I first heard this, I was more than a little concerned. I always thought zombies were just a fun and wildly popular horror movie genre. But could a zom
|
Scooped by
Ed Rybicki
February 7, 2019 10:09 AM
|
This Spotlight focuses on the lessons we can learn from previous flu pandemics, how prepared we are for another one, and how work on seasonal flu can boost capacity for pandemic preparedness.
|
Scooped by
Ed Rybicki
February 7, 2019 10:07 AM
|
A number of meetings have been cancelled...
|
Scooped by
Ed Rybicki
February 6, 2019 2:08 AM
|
Bluetongue virus (BTV), in the family Reoviridae, is an insect-borne, double-capsid virus causing hemorrhagic disease in livestock around the world. Here, we elucidate how outer capsid proteins VP2 and VP5 coordinate cell entry of BTV. To identify key functional residues, we used atomic-level structural data to guide mutagenesis of VP2 and VP5 and a series of biological and biochemical approaches, including site-directed mutagenesis, reverse genetics-based virus recovery, expression and characterization of individual recombinant mutant proteins, and various in vitro and in vivo assays. We demonstrate the dynamic nature of the conformational change process, revealing that a unique zinc finger (CCCH) in VP2 acts as the major low pH sensor, coordinating VP2 detachment, subsequently allowing VP5 to sense low pH via specific histidine residues at key positions. We show that single substitution of only certain histidine residues has a lethal effect, indicating that the location of histidine in VP5 is critical to inducing changes in VP5 conformation that facilitates membrane penetration. Further, we show that the VP5 anchoring domain alone recapitulates sensing of low pH. Our data reveal a novel, multiconformational process that overcomes entry barriers faced by this multicapsid nonenveloped virus. IMPORTANCE Virus entry into a susceptible cell is the first step of infection and a significant point at which infection can be prevented. To enter effectively, viruses must sense the cellular environment and, when appropriate, initiate a series of changes that eventually jettison the protective shell and deposit virus genes into the cytoplasm. Many viruses sense pH, but how this happens and the events that follow are often poorly understood. Here, we address this question for a large multilayered bluetongue virus. We show key residues in outer capsid proteins, a pH-sensing histidine of a zinc finger within the receptor-binding VP2 protein, and certain histidine residues in the membrane-penetrating VP5 protein that detect cellular pH, leading to irreversible changes and propel the virus through the cell membrane. Our data reveal a novel mechanism of cell entry for a nonenveloped virus and highlight mechanisms which may also be used by other viruses.
|
Scooped by
Ed Rybicki
February 2, 2019 6:02 AM
|
We all know that vaccines save lives by preventing diseases.But a new study from Australia provides some solid evidence that the rotavirus vaccine not Source: Rotavirus vaccine may protect children from developing type 1 diabetes...
|
Scooped by
Ed Rybicki
February 2, 2019 5:59 AM
|
NOVOSIBIRSK, February 1. /TASS/. Specialists at the Novosibirsk State Research Center of Virology and Biotechnology VECTOR have completed trials of a vaccine against the Ebola virus disease, which claimed the lives of over 11,000 people in Africa recently, said Nikolai Krasnikov, Head of the Administration of Koltsovo Science City near Novosibirsk where the research center is located, at the TASS press center on Friday. "Our scientists have wrapped up clinical trials of the Ebola vaccine this year. Now it is ready for use," he announced. The World Health Organization describes the Ebola virus disease (EVD, formerly known as Ebola hemorrhagic fever) as "a severe, often fatal illness in humans. EVD outbreaks have a case fatality rate of up to 90%." Symptoms include a sudden onset of fever, intense weakness, muscle pain, a headache and a sore throat. This is followed by vomiting, diarrhea, a rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. The infection is transmitted by direct contact with the blood, body fluids and the tissues of infected animals or people. The incubation period lasts from two to 21 days. The virus was first registered in Zaire (now the Democratic Republic of the Congo) in 1976, with outbreaks reported from Sudan, Gabon, the Republic of the Congo, Angola, and Cote d’Ivoire. The latest Ebola epidemics in West Africa in 2014-2016 killed more than 11,300 people, with more than 28,600 contracting the disease. The most lethal outcomes were reported in Guinea, Sierra Leone and Liberia. Russian doctors and scientists have played an important role in fighting Ebola. In 2017, reports said that an Ebola vaccine had been developed by the Novosibirsk-based VECTOR Research Center. Founded in 1974, VECTOR is one of the world’s largest research centers. Initially, it studied the causative agents of such deadly disease as anthrax and tularemia to create biological weapons based on them. Currently, the center develops tools for diagnosing and treating infectious diseases. Its specialists, in particular, are developing vaccines against swine flu, HIV and Ebola.
|